Can a new value framework help ease friction over orphan drug prices?

7 September 2017 - America’s healthcare debate has stalled in Congress, but constructive dialogue and innovation are thriving in specialised ...

Read more →

FDA’s plan to engage the public in the agency’s new effort to strengthen and modernise FDA’s regulatory framework

7 September 2017 - We’re at a moment of extraordinary opportunity to improve the public health. New innovations are giving us ...

Read more →

Randomised, controlled trials in health insurance systems

6 September 2017 - The well-recognised limitations of traditional randomised, controlled trials, including their cost, the nature of the patients and ...

Read more →

Multidimensional evidence generation and FDA regulatory decision making

22 August 2017 - Evidence linking interventions with health outcomes is the basis for good health care decision making.  ...

Read more →

Using discrete choice experiments to inform the benefit-risk assessment of medicines: are we ready yet?

23 August 2017 - There is emerging interest in the use of discrete choice experiments as a means of quantifying the ...

Read more →

Promoting consumer involvement in medicine decisions welcomed

7 August 2017 - The appointment of consumer leader, Jo Watson, as the inaugural deputy chairperson of the Pharmaceutical Benefits ...

Read more →

Evidence for health decision making — beyond randomised, controlled trials

2 August 2017 - A core principle of good public health practice is to base all policy decisions on the highest-quality ...

Read more →

Dr Steve Pearson on using health technology assessment to guide decision making

23 July 2017 - Health technology assessment is a tool that helps to objectively evaluate evidence, which levels the playing field ...

Read more →

ICER seeks public comment on proposed value assessment framework for treatments that represent a potential major advance for serious ultra-rare conditions

25 July 2017 - ICER’s fundamental approach to value assessment remains constant with proposed changes for special circumstances. ...

Read more →

Managing conflicts of interest – making good decisions

24 July 2017 - NICE is seeking views on a new conflicts of interest policy to ensure its committees’ decisions ...

Read more →

Multidimensional evidence generation and FDA regulatory decision making defining and using “real-world” data

13 July 2017 - Evidence linking interventions with health outcomes is the basis for good health care decision making.  ...

Read more →

SMC industry engagement event

3 July 2017 - The SMC has announced details of the next Scottish Medicines Consortium Industry Engagement Event.  ...

Read more →

Top medicines panel benefits from second consumer representative

 2 June 2017 - The appointment of a second consumers representative to the Pharmaceutical Benefits Advisory Committee recognises the value ...

Read more →

Dr Steve Pearson outlines the importance of thresholds on determining value

23 May 2017 - Thresholds can be useful to focus the conversation around the value of treatments in healthcare even if ...

Read more →

New NICE criteria for drug access

1 May 2017 - An overhaul of NHS drug access in England by NICE and NHS England, which for the first ...

Read more →